Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302156 · ClinicalTrials.gov registry record · Phase 2
PSMA PET and MRI in Gynecological Cancers
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03302156 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 15 participants.
The verdict
NCT03302156, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The goal of this research is to determine the accuracy of PSMA positron emission tomography (PET) and multi-parametric magnetic resonance (MR) imaging to detect the presence of gynecological cancer cells in the body.
Interventions
- DRUG PSMA-based 18F-DCFPyL PET tracer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2020-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03302156
The ClinicalTrials.gov registry entry for NCT03302156 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PSMA-based 18F-DCFPyL PET tracer is the first listed.
NCT03302156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03302156 about?
NCT03302156 is a clinical study titled "PSMA PET and MRI in Gynecological Cancers". The goal of this research is to determine the accuracy of PSMA positron emission tomography (PET) and multi-parametric magnetic resonance (MR) imaging to detect the presence of gynecological cancer cells in the body.
What is the current status of trial NCT03302156?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-11-15. Estimated completion is 2020-01-20.
What interventions are being tested in trial NCT03302156?
The interventions under investigation include: PSMA-based 18F-DCFPyL PET tracer (DRUG).
Who is sponsoring clinical trial NCT03302156?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.